Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original languageEnglish (US)
Pages (from-to)E270-E272
JournalAmerican journal of therapeutics
Issue number2
StatePublished - Mar 1 2018

Bibliographical note

Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.


  • Bortezomib
  • Immune-mediated thrombocytopenia purpura


Dive into the research topics of 'Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura'. Together they form a unique fingerprint.

Cite this